Evidence map›Paper›PMID 40396606›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts.

Yucheng Lu, Daniel Partleton, Filibus M Gugu, Ahmed Y G Alhejaili, Samuel Norris, J Jonathan Harburn, Jason H Gill, Jonathan D Sellars, Alistair K Brown

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yucheng LuBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Daniel PartletonBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Filibus M GuguBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Ahmed Y G AlhejailiBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Samuel NorrisChemistry, School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, UK.
J Jonathan HarburnSchool of Pharmacy, Faculty of Medical Sciences, King George VI Building, Newcastle upon Tyne, UK.
Jason H GillSchool of Pharmacy, Faculty of Medical Sciences, King George VI Building, Newcastle upon Tyne, UK.
Jonathan D SellarsBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Alistair K BrownBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Despite efforts to discover effective treatments to eradicate tuberculosis (TB), it remains a global threat. The increase in drug-resistant bacterial species has made the discovery of new drugs highly coveted. The utilisation of previous efficacious structures is one approach that can be employed to developing novel series of compounds to combat this ever-growing problem. This study sought to re-examine two such compounds, isoxyl (ISO) and SQ109, previously shown to be efficacious in TB treatment. SQ109-ISO hybrid compounds were shown to have demonstrable activity against both drug-sensitive and drug-resistant

Indexed as

AdamantaneAntitubercular AgentsMycobacterium tuberculosisDose-Response Relationship, DrugHumansIsomerismMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAdamantaneAntitubercular AgentsadamantylantitubercularisoxylMycobacteriumSQ109

Identifiers

PMID40396606
PMCPMC12096669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.